Luís Belo

Prof. Dr. Luís Belo

Faculty of Pharmacy, University of Porto, Porto, Portugal
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2005 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
Luís BeloLuís Belo
Luís Belo
Alice Santos-SilvaAlice Santos-Silva
Alice Santos-Silva
Susana RochaSusana Rocha
Susana Rocha
MCMuriel Caslake
Muriel Caslake
JCJosephine Cooney
Josephine Cooney
IRIrene Rebelo
Irene Rebelo


1 June 2002 in Atherosclerosis
Verified
Journal Article
Closed access
Luís BeloLuís Belo
Luís Belo
MCMuriel Caslake
Muriel Caslake
DGDairena Gaffney
Dairena Gaffney
Alice Santos-SilvaAlice Santos-Silva
Alice Santos-Silva
LPLuı́s Pereira-Leite
Luı́s Pereira-Leite
IRIrene Rebelo
Irene Rebelo

7 June 2010 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
Susana CoimbraSusana Coimbra
Susana Coimbra
HOH Oliveira
H Oliveira
Flávio ReisFlávio Reis
Flávio Reis
Luís BeloLuís Belo
Luís Belo
Susana RochaSusana Rocha
Susana Rocha
Alice Santos-SilvaAlice Santos-Silva
Alice Santos-Silva

Verified
Journal Article
Open access
PDF file
ILIrina Lousa
Irina Lousa
Flávio ReisFlávio Reis
Flávio Reis
IBIdalina Beirão
Idalina Beirão
RARui Alves
Rui Alves
Luís BeloLuís Belo
Luís Belo
Alice Santos-SilvaAlice Santos-Silva
Alice Santos-Silva
The prevalence of chronic kidney disease (CKD) is increasing worldwide, and the mortality rate continues to be unacceptably high. The biomarkers currently used in clinical practice are considered relevant when there is already significant renal impairment compromising the early use of potentially successful therapeutic interventions. More sensitive and specific biomarkers to detect CKD earlier on and improve patients’ prognoses are an important unmet medical need. The aim of this review is to summarize the recent literature on new promising early CKD biomarkers of renal function, tubular lesions, endothelial dysfunction and inflammation, and on the auspicious findings from metabolomic studies in this field. Most of the studied biomarkers require further validation in large studies and in a broad range of populations in order to be implemented into routine CKD management. A panel of biomarkers, including earlier biomarkers of renal damage, seems to be a reasonable approach to be applied in clinical practice to allow earlier diagnosis and better disease characterization based on the underlying etiologic process.

6 October 2005 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
PXPedro Xavier
Pedro Xavier
Luís BeloLuís Belo
Luís Belo
JBJorge Beires
Jorge Beires
IRIrene Rebelo
Irene Rebelo
JMJose Martinez-de-Oliveira
Jose Martinez-de-Oliveira
HBHenrique Barros
Henrique Barros